Similar articles

• Genetic variation explains residual CHD risk with statin therapy.

  Le Bras A. Le Bras A. Nat Rev Cardiol. 2018 Aug;15(8):440. doi: 10.1038/s41569-018-0034-8. Nat Rev Cardiol. 2018. PMID: 29777181 No abstract available.
• Statin effects in CKD: is there a "point of no return"?

  Wanner C. Wanner C. Am J Kidney Dis. 2009 May;53(5):723-5. doi: 10.1053/j.ajkd.2009.02.002. Am J Kidney Dis. 2009. PMID: 19393469 No abstract available.
• Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.

  Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T, Wood D, Jünger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJ; DYSIS Investigators. Gitt AK, et al. Eur J Prev Cardiol. 2012 Apr;19(2):221-30. doi: 10.1177/1741826711400545. Epub 2011 Mar 10. Eur J Prev Cardiol. 2012. PMID: 21450578
• Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.

  Robinson JG. Robinson JG. Am J Cardiol. 2008 Apr 1;101(7):1009-15. doi: 10.1016/j.amjcard.2007.11.060. Am J Cardiol. 2008. PMID: 18359323 Review.
• Cholesterol Levels Should Play a More Important Role in Identifying Statin Recipients.

  Durrington PN, Soran H. Durrington PN, et al. Circulation. 2017 Feb 14;135(7):627-629. doi: 10.1161/CIRCULATIONAHA.116.022146. Circulation. 2017. PMID: 28193795 Review. No abstract available.